Santhera Pharmaceuticals Holding AG (XSWX:SANN) EBIT : CHF-45.05 Mil (TTM As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG EBIT?

Santhera Pharmaceuticals Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was CHF-15.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-45.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Santhera Pharmaceuticals Holding AG's annualized ROC % for the quarter that ended in Jun. 2023 was -36.37%. Santhera Pharmaceuticals Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -3,442.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Santhera Pharmaceuticals Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -30.46%.

Santhera Pharmaceuticals Holding AG EBIT Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG EBIT Chart

Santhera Pharmaceuticals Holding AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-49.36

-12.31

-60.57

-38.29

-50.43

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT	Get a 7-Day Free Trial															-8.91	-29.39	-20.78	-29.65	-15.40

Competitive Comparison of Santhera Pharmaceuticals Holding AG's EBIT

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santhera Pharmaceuticals Holding AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-EBIT falls into.

Santhera Pharmaceuticals Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-45.05 Mil.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Santhera Pharmaceuticals Holding AG's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-40.61 * ( 1 - 0.36% )	/	( (101.939	+	120.588)	/ 2 )
=	-40.463804	/	111.2635
=	-36.37 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	63.726	-	8.136	-	( 1.353	-	max(0, 49.414	-	3.065	+	1.353	))
=	101.939

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	63.075	-	9.122	-	( 1.674	-	max(0, 77.379	-	10.744	+	1.674	))
=	120.588

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Santhera Pharmaceuticals Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-30.806	/	( ( (1.008 + max(-24.952, 0))	+	(0.782 + max(-46.322, 0)) )	/	2 )
=	-30.806	/	( ( 1.008	+	0.782 )	/	2 )
=	-30.806	/	0.895
=	-3,442.01 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.438	+	0.108	+	1.166)	-	(8.136	+	0	+	18.528)
=	-24.952

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.971	+	0	+	7.099)	-	(9.122	+	0	+	46.27)
=	-46.322

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Santhera Pharmaceuticals Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-45.052	/	147.883
	=	-30.46 %

Santhera Pharmaceuticals Holding AG EBIT Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (XSWX:SANN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SPHDF:USA SANNz:UK

Address

Hohenrainstrasse 24, Pratteln, CHE, 4133

Website

https://www.santhera.com

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.

Santhera Pharmaceuticals Holding AG (XSWX:SANN) Headlines

No Headlines